A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Martin Eatock

doi:10.1007/s00280-007-0486-8

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

Martin Eatock

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

55 Citations (Scopus)

Original language	English
Pages (from-to)	435-441
Number of pages	7
Journal	Cancer Chemotherapy and Pharmacology
Volume	61(3)
Issue number	3
DOIs	https://doi.org/10.1007/s00280-007-0486-8
Publication status	Published - Mar 2008

ASJC Scopus subject areas

Cancer Research
Pharmacology
Oncology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1007/s00280-007-0486-8

Cite this

@article{b0ace970f7c54af7a428283502299e84,

title = "A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.",

author = "Martin Eatock",

year = "2008",

month = mar,

doi = "10.1007/s00280-007-0486-8",

language = "English",

volume = "61(3)",

pages = "435--441",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

AU - Eatock, Martin

PY - 2008/3

Y1 - 2008/3

UR - http://www.scopus.com/inward/record.url?scp=37249036585&partnerID=8YFLogxK

U2 - 10.1007/s00280-007-0486-8

DO - 10.1007/s00280-007-0486-8

M3 - Article

C2 - 17440725

VL - 61(3)

SP - 435

EP - 441

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -